- Home
- ALGS vs ATNM Comparison
ALGS vs ATNM Comparison
Compare ALGS & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- ATNM
- Stock Information
- Founded
- ALGS 2018
- ATNM 2000
- Country
- ALGS United States
- ATNM United States
- Employees
- ALGS N/A
- ATNM N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- ALGS Health Care
- ATNM Health Care
- Exchange
- ALGS Nasdaq
- ATNM Nasdaq
- Market Cap
- ALGS 53.0M
- ATNM 49.0M
- IPO Year
- ALGS 2020
- ATNM N/A
- Fundamental
- Price
- ALGS $7.70
- ATNM $1.69
- Analyst Decision
- ALGS Strong Buy
- ATNM Strong Buy
- Analyst Count
- ALGS 1
- ATNM 2
- Target Price
- ALGS $70.00
- ATNM $4.50
- AVG Volume (30 Days)
- ALGS 62.6K
- ATNM 213.8K
- Earning Date
- ALGS 08-06-2025
- ATNM 08-08-2025
- Dividend Yield
- ALGS N/A
- ATNM N/A
- EPS Growth
- ALGS N/A
- ATNM N/A
- EPS
- ALGS N/A
- ATNM N/A
- Revenue
- ALGS $3,174,000.00
- ATNM N/A
- Revenue This Year
- ALGS N/A
- ATNM N/A
- Revenue Next Year
- ALGS $51.55
- ATNM N/A
- P/E Ratio
- ALGS N/A
- ATNM N/A
- Revenue Growth
- ALGS N/A
- ATNM N/A
- 52 Week Low
- ALGS $3.76
- ATNM $1.03
- 52 Week High
- ALGS $46.80
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- ALGS 46.70
- ATNM 55.82
- Support Level
- ALGS $7.31
- ATNM $1.39
- Resistance Level
- ALGS $7.85
- ATNM $1.89
- Average True Range (ATR)
- ALGS 0.75
- ATNM 0.12
- MACD
- ALGS -0.09
- ATNM -0.00
- Stochastic Oscillator
- ALGS 35.03
- ATNM 81.08
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.